Aggresome formation and pharmacogenetics: sulfotransferase 1A3 as a model system.

@article{Wang2004AggresomeFA,
  title={Aggresome formation and pharmacogenetics: sulfotransferase 1A3 as a model system.},
  author={Liewei Wang and Vivien C. Yee and Richard M. Weinshilboum},
  journal={Biochemical and biophysical research communications},
  year={2004},
  volume={325 2},
  pages={
          426-33
        }
}
Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation.
TLDR
It is observed that TPMT*3A forms aggresomes in cultured cells and that it aggregates in vitro, functional mechanisms not previously described in pharmacogenetics, which provide insight into a unique pharmacogenetic mechanism by which common polymorphisms affect T PMT protein function and, as a result, therapeutic response to thiopurine drugs.
Arylamine N-acetyltransferases
TLDR
NAT research in the past 5 years builds on that history and additionally paves the way for establishing new concepts in biology and opportunities in drug discovery.
Identification and characterization of genetic variation in the folylpolyglutamate synthase gene.
TLDR
Observations suggest that genetic variations in FPGS may alter the efficacy of antifolate therapy in cancer patients as well as single nucleotide polymorphisms which exist in both the mitochondrial and cytosolic isoforms.
Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in CYP2C9 and CYP2C19
TLDR
High-throughput methods for pharmacogene variant mutagenesis and functional characterization of less-common open reading frame sequence variation might help to individualize therapy with drugs that are substrates for the enzymes encoded by these genes.
SLCO1B1: Application and Limitations of Deep Mutational Scanning for Genomic Missense Variant Function
TLDR
Deep mutational scanning was applied to determine the functional effects of VUS that have been observed in the ORF of SLCO1B1, raising questions with regard to the application of DMS to intrinsic membrane proteins such as organic anion transporter protein 1B1.
CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants
TLDR
DMS is supported as an efficient method for the identification of damaging ORF variants that might have potential clinical pharmacogenomic application after being adapted to study the function of missense variants in the open reading frames of cytochrome P450 family 2 subfamily C member 9 and CYP2C19.
SULT genetic polymorphisms: physiological, pharmacological and clinical implications
TLDR
The information concerning the differential sulfating activities of SULT allozymes toward endogenous compounds may allow for the development of strategies for mitigating anomalies in the metabolism of these endogenous compounds in individuals with certain SULT genotypes.
UDP Glucuronosyltransferase ( UGT ) 1 A 6 Pharmacogenetics : II . Functional Impact of the Three Most Common Nonsynonymous UGT 1 A 6 Polymorphisms ( S 7 A , T 181 A , and R 184 S )
TLDR
There is substantial interindividual variability in the glucuronidation of UGT1A6 substrates by human liver that may have important pharmacological, toxicological, and physiological consequences and there is likely other genetic or environmental factors responsible for the majority of this variation.
Arylamine N-acetyltransferases
TLDR
Transgenic mice are helping to unravel the endogenous role of human NAT1 that is widespread in tissues, expressed very early in development and overexpressed in estrogen-receptor-positive breast cancer.
...
1
2
...

References

SHOWING 1-10 OF 32 REFERENCES
Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation.
TLDR
Observations indicate that TPMT is a client protein for hsp90 and suggest that chaperone proteins play an important mechanistic role in this clinically significant example of pharmacogenetic variation in drug metabolism.
Human sulfotransferase SULT2A1 pharmacogenetics: genotype-to-phenotype studies
TLDR
Observations indicate that common genetic polymorphisms for SULT2A1 can result in reductions in levels of both activity and enzyme protein, and raise the possibility of ethnic-specific pharmacogenetic variation in SULT 2A1-catalyzed sulfation of both endogenous and exogenous substrates for this phase II drug-metabolizing enzyme.
Human catecholamine sulfotransferase (SULT1A3) pharmacogenetics: functional genetic polymorphism
TLDR
The resequencing of SULT1A3 using DNA samples from 60 African‐American and 60 Caucasian‐American subjects raises the possibility of ethnic‐specific inherited alterations in catecholamine sulfation in humans.
Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics
TLDR
It is raised the possibility that genetically determined variation in SULT1E1‐catalyzed estrogen sulfation might contribute to the pathophysiology of estrogen‐dependent diseases as well as variation in the biotransformation of exogenously administered estrogens.
Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism.
TLDR
Molecular cloning and structural characterization of the TPMT gene as well as elucidation of the molecular basis for a common T PMT genetic polymorphism will help make it possible to develop DNA-based diagnostic tests for the polymorphism and to determine the mechanism by which it results in decreased expression of this important drug-metabolizing enzyme.
X-ray Crystal Structure of Human Dopamine Sulfotransferase, SULT1A3
TLDR
QSAR analysis revealed that the SULT1A3 enzyme is highly selective for catechols, and catecholamines in particular, and that hydrogen bonding groups and lipophilicity (cLogD) strongly influenced K m .
Sulfation through the looking glass—recent advances in sulfotransferase research for the curious
  • M. Coughtrie
  • Biology, Chemistry
    The Pharmacogenomics Journal
  • 2002
TLDR
Improved understanding of these enzymes will have significant benefits in such diverse areas as drug design and development, cancer susceptibility, reproduction and development.
Crystal structure of human catecholamine sulfotransferase.
TLDR
Flexibility in regions that are topologically equivalent to the disordered parts of SULT1A3 are involved in substrate and cofactor binding in estrogen and heparan sulfotransferase and might contribute to the broad substrate specificity of these enzymes.
Enzymology of human cytosolic sulfotransferases
  • C. Falany
  • Biology
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 1997
TLDR
An increased understanding of the biochemistry and molecular biology of the STs should also provide additional information as to their functions in many normal physiologic processes.
...
1
2
3
4
...